The Regulations
The original regulations (2) and the revisions (3) were established to ensure that specific infectious agents and tox-ins are shipped only to institutions or individuals equipped to handle them appropriately and only to those who have legitimate reasons to use them. Furthermore, the regulations implement a system whereby scientists and researchers involved in legitimate research may continue transferring and receiving these agents without undue burden.. They also provide a means for tracking the transfer of these select agents. The regulations stem from the "Antiterrorism and Effective Death Penalty Act of 1996." This law requires the Secretary of Health and Human Services to regulate the transfer of certain biological agents (select agents) harmful to humans. The Centers for Disease Control and Prevention (CDC) is responsible for the implementation of this regulation.
The revised regulations address six areas: (i) A list of biological agents (select agents, Table 1 ) that have the potential to pose a severe threat to public health and safety. This list includes approximately 40 viruses, bacteria, rickettsia, fungi, and toxins whose transfer in the U.S. is controlled. (ii) Registration of facilities prior to the transfer of any of these agents. Facilities wishing to register with CDC must submit an application to the CDC, Office of Health and Safety, Laboratory Registration/Select Agent Transfer (LIUSAT) Program. The LR/SAT Program is responsible for this registration and on-site inspection process. The purpose of this section is to assure that the facility meets biosafety level requirements for working with the particular biological agent. (iii) Registered facilities are issued a registration number that must be used when transferring one of these agents from one facility to another: Prior to transfer, both the shipper an&he receiver must be registered with the LR/SAT Program or meet the requirements for exemption. (iv) Each facility shipping or receiving a select agent must designate a "responsible facility offtcial." This official must sign each request, certifying that the requestor of the agent is affiliated with the facility and that the laboratory meets guidelines for working with the requested agent. (v) Facilities must have written procedures for the on-site disposal of select agents. (vi) Exemptions do exist for clinical laboratories and some research facilities. Specific strains of some infectious agents and certain toxins are exempt if used for research purposes, vaccine preparation, or for diagnosis, evaluating treatment, reference, proficiency testing, or verification purposes, or for epidemiological surveillance. Importantly, under certain ' Exemptions: Toxins for medical use, inactivated for use as vaccines, or toxin preparations for biomedical research use for vertebrates of more than 1000 &Kg body weight, and national standard toxins for biologic potency testing as described in 9CFR 113. 'Other restrictions: The deliberate transfer of a drug resistance trait to microorganisms in this table that are not known to acquire the trait naturally is prohibited by National Institute of Heath guidelines (4) if such acquisition could compromise the use of a drug to control these disease agents in human or veterinary medicine.
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Necrotizing enterocolitis (NEC) is an entity that mainly affects premature infants but has been described occasionally in full-term neonates (1). The etiologic roles of the infectious agents in this condition are not yet well established, although NEC has been reported in neonates during the course of bacterial, viral, and mycotic infections (2). In this paper, we describe a full-term neonate who developed NEC in the course of sepsis caused by Streptococcus agalactiae. To our knowledge, NEC has not been previously reported in association with this microorganism.
Case Report
A female infant weighing 3,300 g was born by forceps delivery after an uneventful 36-week gestation. Amniorrhexis occurred intrapartum and the amniotic fluid was clear. Apgar scores were 6 and 7 at 1 and 5 min, respectively. The infant had respiratory distress that started at birth, and she was transferred to our hospital at 12 h of age. Examination on admission showed an ill-appearing, cyanotic, and poorly perfused newborn who had a blood pressure of 53/36 mm Hg, a pulse of 195 beats/min, and respiratory rate of 84lmin. The rectal temperature was 38°C. The infant had respiratory distress and auscultation revealed bilateral hypoventilation and tachycardia. The liver was palpated 4 cm below the right costal margin. She was hypotonic and hypoactive. The anterior fontanelle was flat and there were no meningeal signs.
Laboratory investigation included leukocyte count of 3,100/mm3 with 38% neutrophils, 6% band forms, and 56% lymphocytes. Hemoglobin was 16.7 g/dl; hematocrit, 47.8%; platelet count, 197, OOO/mn?; Quick test, 44%;  and partial thromboplastin time, 68 set (control 30 set). Blood urea was 43 mg/dl and creatinine, 1 mg/dl. Arterial blood gases showed severe hypoxemia, hypercapnia, and mixed acidosis. The urine antigen detection test was positive for group B Streptococcus antigen. A blood culture grew group B Streptococcus. The cerebrospinal fluid analysis was normal and its culture was sterile. Culture of a vaginal swab from the mother yielded group B Streptococcus.
A chest radiograph revealed a micronodular bilateral alveolar pattern.
Bacterial sepsis was initially suspected and the patient was treated with ampicillin, gentamicin, dopamine, dobutamine, plasma therapy, and mechanical ventilation. Umbilical artery and vein catheterizations were performed. Her condition initially improved but deteriorated again on day 3, and she developed a marked abdominal distention with signs of paralytic ileus. An X ray examination of the abdomen at this time showed a large pneumoperitoneum.
After her thrombocytopenia was corrected, a surgical intervention was carried out. At laparotomy, fecal material was found in the abdominal cavity and she had 40 cm of necrotic small bowel. Removal of this loop and a proximal end to distal side anastomosis were performed. The surgi-cal pathology findings showed a congested small bowel with edema, hemorrhage, and ischemic necrosis and wall perforation, compatible with necrotizing enterocolitis.
The patient had a complicated postoperative course with dehiscence of the sutures and outward fistulation. On day 22, she underwent surgery again and resection of another 20 cm of necrotic small bowel was required. After this procedure, the patient had a favorable course with mild symptoms of short bowel syndrome.
Comment
NEC mainly occurs in premature infants but has occasionally been reported in full-term neonates. In most of these cases, predisposing factors are usually present. Although our understanding of the pathogenesis of NEC remains incomplete, the disease seems to have a multifactorial basis (3) (4) (5) Although 20 to 30% of patients with NEC may have an associated bacteremia, most likely this represents bacterial translocation through a previously injured intestinal mucosa rather than the primary initiating event (1). The
